1-3 of 3
Hanying Bao, MD, PhD
Close
Sort by
Journal Articles

Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia

Yuguang Wang, PhD, Hanying Bao, MD PhD, Nong Zhang, PhD, Feilan Wang, PhD, Yunsong He, MD, Tianzhi Wu, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3997.
https://doi.org/10.1182/blood-2018-99-110414
Published: 2018
Journal Articles

Preliminary Results from a Phase I, First-in-Human Study of YY-20394, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Junyuan Qi, PhD, Yuqin Song, MD PhD, Bo Jiang, PhD, Jianyong Li, PhD, Meifeng Tu, PhD, Lingyan Ping, MD PhD, Zengjun Li, PhD, Wei Xu, MD PhD, Huayuan Zhu, MD PhD, Jun Zhu, MD PhD, Hanying Bao, MD PhD, Zusheng Xu, PhD, Lugui Qiu, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5332.
https://doi.org/10.1182/blood-2018-99-110585
Published: 2018
Journal Articles

Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells

Lijuan Wang, MD, PhD, Jianfei Qian, PhD, Yong Lu, PhD, Haiyan Li, MD, PhD, Sungyoul Hong, PhD, Hanying Bao, MD, PhD, Donghua He, MD, PhD, Zhiqiang Liu, PhD, Yuhuan Zheng, PhD, Jin He, PhD, Yongsheng Lan, PhD, Yi Li, MD, Sattva Neelapu, MD, Jing Yang, PhD, Michael Wang, MD, Cai Zhen, MD, PhD, Qing Yi, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2643.
https://doi.org/10.1182/blood.V118.21.2643.2643
Published: 2011